Skip to Content

Laboratory Corp of America Holdings LH

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat




COVID-19 Diagnostic Demand Supports LabCorp's Strong Third-Quarter Results

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

LabCorp delivered stellar third-quarter results, with improvements on the top and bottom lines that were generally consistent with our projections, and we’re leaving our fair value estimate unchanged. With demand for COVID-19 diagnostic tests remaining relatively high, though not quite as high as we’d seen in the second quarter, the benefit of LabCorp’s long-standing investments in its information technology systems and the operating leverage in its network of high-throughput labs came shining through in this quarter. The firm’s impressive efficiency underscores our confidence in its narrow economic moat, which stems from its significantly lower cost structure.

Read Full Analysis

Company Profile

Business Description

Laboratory Corporation of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing. With the addition of Covance, LabCorp also has a sizable footprint in the global contract research organization market.

358 South Main Street
Burlington, NC, 27215
T +1 336 229-1127
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 65,000